Longeveron Inc.
LGVNLongeveron Inc. in brief
Longeveron Inc. is a listed company in the Biotechnology industry, based in Miami, Florida, USA. It was founded in 2014. Its market value was $24 M on 1 August 2026, which makes it the 23,744th largest listed company in the world and the 4,100th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $23 M. It employs about 37 people and Stephen H. Willard is its chief executive. Its largest product and service lines by sales in 2025 were Clinical trial revenue (80%), Contract manufacturing revenue (19%) and Contract manufacturing lease revenue (2%). Its shares trade under the symbol LGVN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Longeveron Inc.
We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®.
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. Laromestrocel possesses broad potential applications across a spectrum of disease areas. Our mission is to continue to advance the development and regulatory approval of laromestrocel in order to make it available for patients who may need it.
From the company's annual report filed with the US SEC: read the report
Longeveron Inc. timeline
- 2014
- 🏁· approximateFounded
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- ✎Renamed Longeveron Inc.Formerly Longeveron Llc.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 12 February 2021; shares registered for exchange trading on 11 February 2021.
Events of Longeveron Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,827 (Jan 2022) · #4,557 (Dec 2022) · #4,506 (Jul 2023) · #4,232 (Jan 2024) · #2,378 (Mar 2026) · #3,912 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 20.5×
- Price / book
- 4.2×
- Free cash flow yield
- -78.7%
- Net margin (TTM)
- -1913.7%
- Operating margin
- -1940.8%
- Return on equity
- -394.2%
- Liabilities / assets
- 44.7%
- Net debt
- $-1M
- Revenue growth
- -49.8%
- R&D / revenue
- 1003.3%
- Revenue per employee
- $32 K
- Profit per employee
- $-614 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | -49.8% | $-23M | $-23M | -1891.7% |
| Dec 2024 | $2M | +236.6% | $-17M | $-16M | -668.2% |
| Dec 2023 | $1M | -41.8% | $-21M | $-21M | -3015.5% |
| Dec 2022 | $1M | -6.9% | $-18M | $-19M | -1544.3% |
| Dec 2021 | $1M | -76.7% | $-17M | $-17M | -1300.8% |
| Dec 2020 | $6M | — | $-4M | $-4M | -66.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-19M | $0M | $-19M | $-1.29 | — |
| Dec 2024 | $-14M | $1M | $-15M | $-2.62 | — |
| Dec 2023 | $-19M | $0M | $-19M | $-10.22 | — |
| Dec 2022 | $-14M | $1M | $-15M | $-0.90 | — |
| Dec 2021 | $-10M | $0M | $-10M | $-0.90 | — |
| Dec 2020 | $-2M | $0M | $-2M | $-0.23 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (-14.3% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportDirectors or officers changed
- Oct 26, 20268-KCurrent reportOther events
- Oct 14, 20268-KCurrent reportDirectors or officers changed
- Sep 23, 20268-KCurrent reportOther events
- Sep 14, 20268-KCurrent reportOther events
- Aug 24, 20268-KCurrent reportBylaws amended · Regulation FD disclosure
- Aug 19, 20268-KCurrent reportDirectors or officers changed
- Aug 12, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Jul 29, 20268-KCurrent reportOther events
Official filings of Longeveron Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-23 M
- Net income
- $-23 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $10 M
- Total liabilities
- $5 M
- Total equity
- $6 M
As of December-2025
Top 18 institutional investors in Longeveron Inc.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Logos Global Management LP | 192,308 | New | $1 M | Nov 16, 2026 |
| 2 | Janus Henderson Group Ltd. | 128,699 | — | $0 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 72,787 | New | $0 M | Nov 13, 2026 |
| 4 | Geode Capital Management, LLC | 25,119 | New | $0 M | Nov 6, 2026 |
| 5 | BlackRock, Inc. | 22,416 | New | $0 M | Nov 13, 2026 |
| 6 | HRT Financial LP | 15,294 | New | $0 M | Nov 13, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 14,012 | New | $0 M | Nov 13, 2026 |
| 8 | ADAR1 Capital Management, LLC | 10,840 | New | $0 M | Nov 16, 2026 |
| 9 | Beacon Pointe Advisors, LLC | 10,000 | New | $0 M | Nov 16, 2026 |
| 10 | Tower Research Capital LLC (TRC) | 2,101 | New | $0 M | Nov 16, 2026 |
| 11 | Jones Financial Companies Lllp | 300 | New | $0 M | Nov 13, 2026 |
| 12 | Steward Partners Investment Advisory, LLC | 238 | New | $0 M | Nov 13, 2026 |
| 13 | SBI Securities Co., Ltd. | 226 | New | $0 M | Oct 22, 2026 |
| 14 | Osaic Holdings, Inc. | 200 | New | $0 M | Nov 12, 2026 |
| 15 | Allworth Financial LP | 13 | New | $0 M | Nov 17, 2026 |
| 16 | FMR LLC | 2 | New | $0 M | Nov 10, 2026 |
| 17 | UBS Group AG | 2 | New | $0 M | Nov 10, 2026 |
| 18 | Danske Bank A/s | 1 | New | $0 M | Nov 9, 2026 |
Mutual funds holding Longeveron Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 361,300 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 180,732 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 116,119 | $0 M | — | <0.01% | +63% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 23,926 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 20,397 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 2,931 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Longeveron Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Devin BlassCTO & SVP of CMC | Shares withheld for tax | -2,520 | $2.590 | $7 K | 68,653 | Form 4 |
| filed | Paul T. LehrGeneral Counsel, Secretary | Shares withheld for tax | -2,253 | $2.590 | $6 K | 83,889 | Form 4 |
| filed | Nataliya AgafonovaChief Medical Officer | Shares withheld for tax | -2,913 | $2.590 | $8 K | 68,778 | Form 4 |
| filed | Stephen H. WillardChief Executive Officer | Shares withheld for tax | -1,987 | $2.590 | $5 K | 74,916 | Form 4 |
| filed | Nirav S. JhaveriChief Financial Officer | Shares withheld for tax | -742 | $2.590 | $2 K | 29,258 | Form 4 |
| filed | Leah Rush CannDirector | Grant or award | +36,000 | — | — | 36,000 | Form 4 |
| filed | Deborah AscheimDirector | Grant or award | +36,000 | — | — | 36,000 | Form 4 |
| filed | Nataliya AgafonovaChief Medical Officer | Grant or award | +286,000 | — | — | 716,914 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Longeveron Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-09-16 20:55 UTC, code T3, resumed 21:55 UTC
- 2026-08-26 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-08-08 17:29 UTC, code LUDP, resumed 17:34 UTC
Fails to deliver
- : 11,542 shares at $1.73
- : 11,493 shares at $1.59
- : 1,007 shares at $1.50
- : 5,623 shares at $2.45
- : 1,226 shares at $2.44
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Longeveron Inc. scorecard#
Passes 1 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 6
- ✗Revenue grew in the newest year-49.8%Revenue down 49.8% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-0.6%-0.6% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-0.6%-0.6% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.29 vs -2.62Diluted EPS -1.29 in fiscal 2025 against -2.62 the year before (report's currency).
- ✗Net income higher than five years earlier-$23 M-$23 M in fiscal 2025 against -$4 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$23 MNet income -$23 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-164.7%-164.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.3×Current ratio 1.33 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-22.13Z-score -22.13 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year86.8%Diluted shares up 86.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Longeveron Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Return on equity | -164.7% | -61.0% | |
| Revenue growth, 3 years a year | -0.6% | 12.9% | |
| Revenue growth | -49.8% | 15.8% |
2of 8on the Piotroski tests of financial strength
- Revenue fell 49.8% against the year before.
- Net loss of $23 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$19 million.
- The share count rose 86.8% in the year.
Longeveron Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1.2−49.9%100% | 2.4+237%100% | 0.7−42.0%100% | 1.2−6.4%100% | 1.3−76.8%100% | 5.6—100% | |
| Cost of revenue | 0.4−22.0%33.0% | 0.5+4.1%21.2% | 0.5−32.7%68.8% | 0.7+1.3%59.3% | 0.7−81.2%54.8% | 3.8—67.6% | |
| Gross profit | 0.8−57.4%67.0% | 1.9+752%78.8% | 0.2−55.5%31.2% | 0.5−15.8%40.7% | 0.6−67.7%45.2% | 1.8—32.4% | |
| Research and development | 12+48.0%1004% | 8.1−10.2%340% | 9.1−3.2%1279% | 9.4+32.1%767% | 7.1+165%543% | 2.7—47.5% | |
| Selling and marketing | — | — | 0.8−25.5%110% | 1.1−13.4%86.0% | 1.2r0.2+510%93.0% | 0.2—3.5% | |
| General and administrative | 12+17.3%1005% | 10−15.7%429% | 12r11+50.1%1718% | 8.1−16.6%664% | 9.7r11+257%746% | 2.7—48.5% | |
| Operating expenses | 24+30.9%2009% | 18−13.4%769% | 21+14.6%2997% | 19+2.7%1517% | 18+222%1382% | 5.6—99.6% | |
| Operating income | −23—−1942% | −17—−691% | −21—−2966% | −18—−1477% | −17—−1337% | −3.8—−67.1% | |
| Interest expense and finance costs | — | — | — | 1.4+34850%114% | 0.0−42.9%0.3% | 0.0—0.1% | |
| Other non-operating income (expense) | 0.6+6.2%48.6% | 0.5—23.0% | −0.4—−54.2% | −0.8−293%−64.8% | 0.4+621%31.5% | 0.1—1.0% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | |
| Net income including minority interests | — | — | — | — | −17—−1305% | −3.7—−66.1% | |
| Net income attributable to shareholders | −23—−1894% | −16—−668% | −21—−3020% | −19—−1541% | −17—−1305% | −3.7—−66.1% | |
| Earnings per share, basic | -1.29—— | -2.62—— | -10.22r-1.02—— | -0.90—— | -0.90—— | -0.23—— | |
| Earnings per share, diluted | -1.29—— | -2.62—— | -10.22r-1.02—— | -0.90—— | -0.90—— | -0.23—— | |
| Shares, weighted average (basic) | 17,577+86.8%— | 9,411+333%— | 2,173r22+10265%— | 21+10.9%— | 19—— | — | |
| Shares, weighted average (diluted) | 17,577+86.8%— | 9,411+333%— | 2,173r22+10265%— | 21+10.9%— | 19+18.0%— | 16—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 4.7−75.8%45.4% | 19+289%75.2% | 4.9−52.9%41.0% | 11−59.1%38.3% | 26+3044%60.0% | 0.8—8.8% | |
| Short-term investments | — | 0−100%0.0% | 0.4−95.5%3.4% | 9.2−3.3%33.4% | 9.5—22.1% | — | |
| Receivables | 0.1+23.8%1.0% | 0.1−24.3%0.3% | 0.1−49.1%0.9% | 0.2+296%0.8% | 0.1—0.1% | — | |
| Other current assets | 0.7+123%6.7% | 0.3−18.1%1.2% | 0.4−6.9%3.1% | 0.4+43.3%1.5% | 0.3+442%0.7% | 0.1—0.6% | |
| Current assets | 5.5−72.2%53.1% | 20+236%76.8% | 5.8−71.2%48.4% | 20−42.7%74.0% | 35r35+1813%82.7% | 1.8—20.0% | |
| Property, plant and equipment | 1.8−25.0%17.9% | 2.4−3.2%9.6% | 2.5−14.2%20.9% | 2.9−3.7%10.8% | 3.1−14.9%7.2% | 3.6—38.9% | |
| Right-of-use (leased) assets | 0.5−41.8%5.0% | 0.9−27.8%3.5% | 1.2−20.2%10.1% | 1.5−15.6%5.6% | 1.8r1.8−13.7%4.2% | 2.1—22.7% | |
| Other intangible assets | 2.3−4.8%22.3% | 2.4+5.0%9.4% | 2.3−5.1%18.9% | 2.4+3.2%8.8% | 2.3+50.9%5.5% | 1.5—16.7% | |
| Total assets | 10−59.9%100% | 26+112%100% | 12−55.9%100% | 27−35.9%100% | 43+363%100% | 9.2—100% | |
| Accounts payable | 0.4+327%4.1% | 0.1−84.5%0.4% | 0.6−63.6%5.3% | 1.8+171%6.4% | 0.6−59.4%1.5% | 1.6—17.2% | |
| Debt due within a year | — | — | — | — | — | 0.1r0.1—1.5% | |
| Current liabilities | 4.1+58.3%39.8% | 2.6−33.6%10.1% | 3.9−20.1%32.2% | 4.9+79.8%17.8% | 2.7−29.3%6.3% | 3.8—41.5% | |
| Lease liabilities (non-current) | 0.2−79.5%1.6% | 0.8−43.1%3.2% | 1.4−29.1%12.0% | 2.0—7.4% | — | — | |
| Non-current liabilities | 0.5−54.2%4.9% | 1.1−24.8%4.3% | 1.4−29.1%12.0% | 2.0—7.4% | — | — | |
| Total liabilities | 4.6+24.9%44.7% | 3.7−31.2%14.4% | 5.3−22.8%44.2% | 6.9+30.1%25.2% | 5.3−27.0%12.4% | 7.3—78.8% | |
| Retained earnings | −132—−1289% | −110—−429% | −85—−704% | −63—−229% | −44—−103% | — | |
| Shareholders' equity | 5.7−74.1%55.3% | 22+225%85.6% | 6.7−67.1%55.8% | 21−45.3%74.8% | 37+1814%87.6% | 2.0r2.0—21.2% | |
| Total liabilities and equity | 10−59.9%100% | 26+112%100% | 12−55.9%100% | 27−35.9%100% | 43+363%100% | 9.2—100% | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.8+14.3%66.7% | 0.70.0%29.3% | 0.70.0%98.7% | 0.7r0.0+99999900%57.3% | 0.00.0%0.0% | 0.0—0.0% | |
| Share-based compensation | 1.7−28.0%140% | 2.3+14.6%97.3% | 2.0−6.2%287% | 2.2r0.2+67.1%177% | 1.3+2848%99.3% | 0.0—0.8% | |
| Cash from operating activities | −19—−1555% | −14—−580% | −19—−2680% | −14—−1143% | −9.6—−738% | −2.4—−42.0% | |
| Capital expenditure | −0.2—−20.4% | −0.7—−27.4% | −0.3—−42.5% | −0.6—−46.6% | −0.3—−25.3% | −0.1—−2.3% | |
| Intangible assets bought | −0.4—−29.2% | −0.3—−14.1% | −0.4—−55.4% | −0.3—−23.5% | −1.0—−75.0% | −0.1—−2.3% | |
| Cash from investing activities | −0.6—−49.6% | −0.6−108%−26.8% | 8.2—1155% | −0.7—−55.4% | −11—−819% | −0.3—−4.6% | |
| Debt issued | — | — | — | — | — | 0.5—8.0% | |
| Shares issued | 5.0−61.3%415% | 13+141%538% | 5.3+266800%753% | 0.0−100.0%0.2% | 27—2044% | — | |
| Cash from financing activities | 4.7−83.8%389% | 29+447%1204% | 5.3—742% | −0.5−101%−41.7% | 45+2768%3459% | 1.6—28.0% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 1.2−18.9%100% | 0.1−16.1%100% | 0.3−9.2%100% | 0.4+4.5%100% | 0.4*−39.5%100% | 0.1−82.3%100% | 0.3−32.5%100% | 0.4−30.5%100% | 0.6*+857%100% | 0.8—100% | 0.5—100% | 0.5—100% | 0.1*—100% | |
| Cost of revenue | 0.4+8.3%33.6% | 0.0+267%38.3% | 0.1−38.2%36.6% | 0.1+26.4%33.7% | 0.1*+47.9%29.6% | 0.0−86.8%8.8% | 0.2+37.1%53.8% | 0.1−51.6%27.8% | 0.1*+12.3%12.1% | 0.1—11.8% | 0.1—26.5% | 0.2—40.0% | 0.1*—103% | |
| Gross profit | 0.8−28.1%66.4% | 0.1−43.2%61.7% | 0.2+24.7%63.4% | 0.3−4.0%66.3% | 0.3*−51.5%70.4% | 0.1−81.7%91.2% | 0.1−57.6%46.2% | 0.3−16.4%72.2% | 0.5*—87.9% | 0.7—88.2% | 0.3—73.5% | 0.3—60.0% | −0.0*—−3.2% | |
| Research and development | 12+7.8%1046% | 4.0+2.8%3442% | 3.2+8.1%1113% | 2.3−7.8%583% | 2.7*+36.8%745% | 3.9+74.6%2812% | 3.0+71.5%935% | 2.5+13.3%660% | 2.0*−7.7%330% | 2.2—285% | 1.7—368% | 2.2—405% | 2.2*—3422% | |
| Selling and marketing | — | — | — | — | — | — | — | — | — | — | — | — | 0.2*—322% | |
| General and administrative | 12+1.6%1041% | 3.3−7.6%2878% | 3.2+22.0%1101% | 2.7−7.5%683% | 2.9*+4.0%804% | 3.6+14.7%2615% | 2.6+22.0%819% | 2.9+33.7%772% | 2.8*−14.0%468% | 3.1—404% | 2.1—453% | 2.2—401% | 3.3r3.1*—5210% | |
| Operating expenses | 24+4.6%2087% | 7.3−2.2%6320% | 6.4+14.6%2214% | 5.0−7.6%1266% | 5.7*+17.6%1550% | 7.4+39.5%5427% | 5.5+44.2%1754% | 5.5+23.5%1432% | 4.8*−11.5%798% | 5.3—690% | 3.8—821% | 4.4—806% | 5.4*—8632% | |
| Operating income | −24—−2021% | −7.2—−6258% | −6.2—−2150% | −4.8—−1200% | −5.4*—−1479% | −7.3—−5336% | −5.4—−1708% | −5.2—−1360% | −4.3*—−710% | −4.6—−601% | −3.5—−748% | −4.1—−746% | −5.4*—−8635% | |
| Other non-operating income (expense) | 1.2+39.4%99.1% | 1.1+1093%923% | 0.1−73.4%34.1% | 0.0−77.1%9.8% | −0.0*−123%−12.3% | 0.1−61.3%65.0% | 0.4+324%117% | 0.2+431%44.6% | 0.2*—33.2% | 0.2—29.8% | 0.1—18.6% | 0.0—5.8% | −0.6*—−933% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | |
| Net income attributable to shareholders | −22—−1922% | −6.1—−5335% | −6.1—−2116% | −4.7—−1190% | −5.4*—−1492% | −7.2—−5271% | −5.0—−1591% | −5.0—−1315% | −4.1*—−677% | −4.4—−572% | −3.4—−729% | −4.1—−741% | −6.0*—−9568% | |
| Earnings per share, basic | — | -1.91—— | -0.19—— | -0.19—— | — | -3.93r-0.39—— | -0.33—— | -0.34—— | — | -0.34—— | -1.83—— | -1.61—— | — | |
| Earnings per share, diluted | — | -1.91—— | -0.19—— | -0.19—— | — | -3.93r-0.39—— | -0.33—— | -0.34—— | — | -0.34—— | -1.83—— | -1.61—— | — | |
| Shares, weighted average (basic) | 3.2+74.8%— | 3.2+74.8%— | 31+109%— | 24,786+65.8%— | — | 1.8r18,373−100.0%— | 15r15,013−99.8%— | 14,951+495%— | — | 13,628—— | 6,510r6.5—— | 2,514r2.5—— | — | |
| Shares, weighted average (diluted) | 3.2+74.8%— | 3.2+74.8%— | 31+109%— | 24,786+65.8%— | — | 1.8r18,373−100.0%— | 15r15,013−99.8%— | 14,951+495%— | — | 13,628—— | 6,510r6.5—— | 2,514r2.5—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 7.2—60.3% | 7.2−21.6%60.3% | 10−2.5%65.1% | 16+10.0%74.3% | 4.7−75.8%45.4% | 9.2−59.4%59.4% | 10−16.5%61.7% | 14+639%68.7% | 19+289%75.2% | 23—76.2% | 12—63.8% | 1.9—20.0% | 4.9—41.0% | |
| Short-term investments | — | — | — | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0—0.0% | — | 0.4—3.6% | 0.4—3.4% | |
| Receivables | 0.1—0.5% | 0.1+23.1%0.5% | 0.1+110%0.4% | 0.1+134%0.3% | 0.1+23.8%1.0% | 0.1−86.3%0.3% | 0.0−85.8%0.2% | 0.0−83.7%0.1% | 0.1−24.3%0.3% | 0.4—1.3% | 0.2—1.1% | 0.2—1.8% | 0.1—0.9% | |
| Other current assets | 0.8—7.0% | 0.8−19.5%7.0% | 1.2+30.6%7.6% | 1.0+12.0%4.9% | 0.7+123%6.7% | 1.0+71.4%6.7% | 0.9+10.6%5.4% | 0.9−28.6%4.4% | 0.3−18.1%1.2% | 0.6—2.0% | 0.8—4.2% | 1.3—13.3% | 0.4—3.1% | |
| Current assets | 8.1—67.8% | 8.1−21.2%67.8% | 11+0.5%73.1% | 17+10.3%79.5% | 5.5−72.2%53.1% | 10−56.5%66.5% | 11−16.0%67.3% | 15+307%73.3% | 20+236%76.8% | 24—79.5% | 13—69.1% | 3.8—38.7% | 5.8—48.4% | |
| Property, plant and equipment | 1.4—12.0% | 1.4−31.9%12.0% | 1.6−29.1%10.3% | 1.7−27.8%7.8% | 1.8−25.0%17.9% | 2.1−19.1%13.6% | 2.3−4.8%13.5% | 2.3−2.6%11.0% | 2.4−3.2%9.6% | 2.6—8.8% | 2.4—12.2% | 2.3—24.2% | 2.5—20.9% | |
| Right-of-use (leased) assets | 0.2—2.0% | 0.2−59.5%2.0% | 0.3−50.4%2.2% | 0.4−43.5%2.1% | 0.5−41.8%5.0% | 0.6−37.3%3.9% | 0.7−33.6%4.2% | 0.8−30.4%3.8% | 0.9−27.8%3.5% | 1.0—3.2% | 1.1—5.4% | 1.1—11.7% | 1.2—10.1% | |
| Other intangible assets | 2.2—18.0% | 2.2−6.1%18.0% | 2.2−5.1%14.2% | 2.2−2.3%10.6% | 2.3−4.8%22.3% | 2.3−1.6%14.8% | 2.3−1.4%13.9% | 2.3+1.2%11.0% | 2.4+5.0%9.4% | 2.3—7.8% | 2.4—12.1% | 2.3—23.3% | 2.3—18.9% | |
| Total assets | 12—100% | 12−22.8%100% | 15−7.5%100% | 21+1.7%100% | 10−59.9%100% | 16−48.0%100% | 17−13.6%100% | 21+115%100% | 26+112%100% | 30—100% | 19—100% | 9.7—100% | 12—100% | |
| Accounts payable | 2.0—16.3% | 2.0+81.6%16.3% | 0.6−9.6%4.1% | 0.3−20.2%1.4% | 0.4+327%4.1% | 1.1+21.8%6.9% | 0.7+16.7%4.2% | 0.4−75.0%1.8% | 0.1−84.5%0.4% | 0.9—3.0% | 0.6—3.1% | 1.5—15.1% | 0.6—5.3% | |
| Current liabilities | 6.5—54.3% | 6.5+32.1%54.3% | 4.3+31.2%27.8% | 4.3+59.5%20.5% | 4.1+58.3%39.8% | 4.9+59.4%31.8% | 3.3+2.3%19.6% | 2.7−48.6%13.1% | 2.6−33.6%10.1% | 3.1—10.4% | 3.2—16.6% | 5.3—54.6% | 3.9—32.2% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0.1−91.0%0.3% | 0.2−79.5%1.6% | 0.3−65.8%2.2% | 0.5−56.1%3.0% | 0.7−48.7%3.2% | 0.8−43.1%3.2% | 1.0—3.3% | 1.1—5.9% | 1.3—13.4% | 1.4—12.0% | |
| Non-current liabilities | 0.8—6.5% | 0.8+19.5%6.5% | 0.8−3.8%5.0% | 0.8−13.3%4.0% | 0.5−54.2%4.9% | 0.7−44.9%4.2% | 0.8−36.4%4.8% | 1.0−29.0%4.6% | 1.1−24.8%4.3% | 1.2—4.0% | 1.3—6.6% | 1.4—14.0% | 1.4—12.0% | |
| Total liabilities | 7.3—60.8% | 7.3+30.7%60.8% | 5.1+24.2%32.8% | 5.2+40.5%24.4% | 4.6+24.9%44.7% | 5.6+30.6%35.9% | 4.1−8.7%24.4% | 3.7−44.6%17.7% | 3.7−31.2%14.4% | 4.3—14.3% | 4.5—23.1% | 6.7—68.6% | 5.3—44.2% | |
| Retained earnings | −149—−1242% | −149—−1242% | −143—−924% | −137—−646% | −132—−1289% | −127—−815% | −120—−714% | −115—−550% | −110—−429% | −106—−353% | −101—−521% | −89—−918% | −85—−704% | |
| Shareholders' equity | 4.7—39.2% | 4.7−52.7%39.2% | 10−17.8%67.2% | 16−6.6%75.6% | 5.7−74.1%55.3% | 10.0−61.1%64.1% | 13−15.1%75.6% | 17+464%82.3% | 22+225%85.6% | 26—85.7% | 15r15—76.9% | 3.0—31.4% | 6.7—55.8% | |
| Total liabilities and equity | 12—100% | 12−22.8%100% | 15−7.5%100% | 21+1.7%100% | 10−59.9%100% | 16−48.0%100% | 17−13.6%100% | 21+115%100% | 26+112%100% | 30—100% | 19—100% | 9.7—100% | 12—100% | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.80.0%68.7% | 0.20.0%174% | 0.20.0%69.7% | 0.20.0%50.3% | 0.2*0.0%54.8% | 0.20.0%146% | 0.20.0%63.3% | 0.20.0%52.5% | 0.2*0.0%33.2% | 0.2—25.9% | 0.2—42.7% | 0.2—36.5% | 0.2*—317% | |
| Share-based compensation | 1.6−2.5%141% | 0.5*+16.1%452% | 0.4*−27.3%130% | 0.4+11.5%95.2% | 0.4*−3.6%103% | 0.4*−68.3%327% | 0.5*+123%162% | 0.3+15.3%89.2% | 0.4*−5.6%64.7% | 1.4*—183% | 0.2*—49.1% | 0.3—53.8% | 0.4*—656% | |
| Cash from operating activities | −18—−1546% | −2.7*—−2337% | −5.7*—−1970% | −4.4—−1098% | −5.3*—−1451% | −5.1*—−3690% | −3.6*—−1138% | −4.7—−1233% | −3.4*—−559% | −2.8*—−368% | −4.6*—−976% | −3.1—−563% | −4.0*—−6344% | |
| Capital expenditure | −0.2—−14.4% | −0.1*—−56.5% | −0.1*—−35.9% | 0—0.0% | 0*—0.0% | −0.1*—−41.6% | −0.2*—−50.9% | −0.0—−7.1% | −0.0*—−2.2% | −0.4*—−55.6% | −0.2*—−41.9% | −0.0—−2.9% | −0.2*—−260% | |
| Intangible assets bought | −0.1—−7.3% | −0.0*—−0.9% | 0*—0.0% | −0.0—−5.0% | −0.1*—−17.5% | −0.1*—−44.5% | −0.1*—−32.3% | −0.1—−32.3% | −0.1*—−18.2% | −0.1*—−6.5% | −0.1*—−31.2% | −0.0—−5.7% | −0.1*—−151% | |
| Cash from investing activities | −0.3—−21.7% | −0.1*—−57.4% | −0.1*—−35.9% | −0.0—−5.0% | −0.1*—−17.5% | −0.1*—−86.1% | −0.3*—−83.2% | −0.2−1171%−39.4% | −0.1*−108%−20.4% | −0.5*—−61.8% | −0.1*—−11.3% | 0.0—2.6% | 1.6*—2483% | |
| Shares issued | — | — | — | — | 0.8*—229% | — | — | — | 0*—0.0% | 8.1*—1054% | 4.6*—988% | 0.1—18.2% | — | |
| Cash from financing activities | 16+323%1396% | −0.1*−102%−67.8% | 0.1*—26.1% | 15—3891% | 0.8*—213% | 4.1*−70.2%2980% | −0.1*−101%−42.1% | −0.1−192%−15.2% | −0.1*−101%−8.3% | 14*—1775% | 15*—3217% | 0.1—11.5% | 5.4*—8595% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Longeveron Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Clinical trial revenue$1 M80%-32%
- Contract manufacturing revenue$0 M19%-55%
- Contract manufacturing lease revenue$0 M1.9%-96%
Business segments
- Reportable$1 M100%-50%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Longeveron Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Directors and officers 13 · Material agreement 3 · Unregistered share sale 1 · Bylaws or fiscal year changed 3 · Shareholder vote 1 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Delisting noticeDirectors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Longeveron Inc. compares in Biotechnology
- Market cap$24 M · higher than 19% of 726
- Revenue$1 M · higher than 26% of 647
- Revenue growth-49.8% · higher than 19% of 438
- Price / sales20.5× · lower than 31% of 339
- Price / book4.2× · lower than 37% of 534
- FCF yield-78.7% · higher than 13% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Longeveron Inc.🇺🇸 | $24 M | — | — | -49.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Longeveron Inc.? Verify and update this profile — free
Show Longeveron Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.